Previous close | 0.2200 |
Open | 0.2200 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.2200 - 0.2200 |
52-week range | 0.2200 - 1.0000 |
Volume | |
Avg. volume | 0 |
Market cap | 86.917M |
Beta (5Y monthly) | 0.44 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0200 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Please find the HBC Company Presentation attached. For further information, please contact: James Berger, Chief Commercial Officer of Hofseth BioCare ASA Phone: +41 79 950 10 34 E-mail: jb@hofsethbiocare.no About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new pharmaceutical drug leads. Research is ongoing to identify the individual elements within its ingredients that modulate inflammation and the immune response with pre-clinical stu
Kristin Fjellby Grung, Chair of the Board of Hofseth BioCare ASA, has informed the Board of Directors that she will resign from the position on 31 March 2024, as she will assume a position as judge in the District Court of Møre and Romsdal and will therefore not be able to continue to serve in the position as Chair of the Board. Grung has been a member of the Board of Directors since December 2020, and assumed the position as Chair in April 2022. The Board would like to thank Grung for her servi
HBC had gross operating revenues of NOK 47.4m (33.6m) in the fourth quarter and NOK 218.5m (120.4m) for the full year. Adjusted for the sale of assets in the second quarter, operating revenues were NOK 194.9m for the full year, representing an increase compared to 2022 of 38 percent. Cash and cash equivalents increased by NOK 6.2m during the quarter, leaving total holding at NOK 23.9m at the end of the year, compared to NOK 32.4m at the end of 2022. Including credit facilities, HBC had NOK 62.5m